Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in BMY — Bristol Myers Squibb Co

CIK 1423053 MIAMI, FL
Back to BMY Full portfolio

Position in BMY

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$90,625,291
+$35,473,745 QoQ
Shares Held
1,494,234
+46.1% QoQ
Ownership
0.073%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in BMY Over Time

Shares Held

Position Value (USD)

Derivatives in BMY

reported options exposure · as of Mar 31, 2026
CallValue
$290,028,300
CallShares
4,782,000
PutValue
$197,349,035
PutShares
3,253,900

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $2,757,631,879 across 16 Drug Manufacturers - General names. BMY ranks #9 (3.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 GILD
Gilead Sciences, Inc.
 3,982,185 $554,997,122
2 JNJ
Johnson & Johnson
 1,930,976 $472,007,773
3 MRK
Merck & Co., Inc.
 3,821,227 $459,655,395
4 AZN
Astrazeneca PLC
 1,869,793 $368,760,574
5 LLY
ELI LILLY & Co
 241,714 $222,321,285
6 PFE
Pfizer Inc
 7,359,865 $206,665,008
7 ABBV
AbbVie Inc.
 490,285 $106,632,084
8 NVO
Novo Nordisk A S
 2,736,525 $100,567,293

All Filings in BMY

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $90,625,291 1,494,234
2026-03-31 $197,349,035 3,253,900
2026-03-31 $290,028,300 4,782,000
2025-12-31 $215,630,544 3,997,600
2025-12-31 $212,965,908 3,948,200
2025-12-31 $55,151,546 1,022,461
2025-09-30 $172,926,930 3,834,300
2025-09-30 $176,088,440 3,904,400
2025-09-30 $109,707,689 2,432,543
2025-06-30 $135,527,862 2,927,800
2025-06-30 $40,677,383 878,751
2025-06-30 $163,380,555 3,529,500
2025-03-31 $288,629,076 4,732,400
2025-03-31 $17,452,471 286,153
2025-03-31 $217,624,518 3,568,200
2024-12-31 $221,856,600 3,922,500
2024-12-31 $273,037,744 4,827,400
2024-12-31 $2,349,445 41,539
2024-09-30 $263,156,624 5,086,135
2024-09-30 $357,963,190 6,918,500
2024-09-30 $369,418,426 7,139,900
2024-06-30 $237,543,294 5,719,800
2024-06-30 $455,653,745 10,971,677
2024-06-30 $367,889,352 8,858,400
2024-03-31 $269,832,211 4,975,700
2024-03-31 $16,896,712 311,575
2024-03-31 $211,404,809 3,898,300
2023-12-31 $144,432,519 2,814,900
2023-12-31 $147,516,250 2,875,000
2023-12-31 $153,213,814 2,986,042
2023-09-30 $159,760,904 2,752,600
2023-09-30 $49,957,581 860,744
2023-09-30 $140,067,932 2,413,300
2023-06-30 $76,011,545 1,188,609
2023-06-30 $185,180,015 2,895,700
2023-06-30 $96,155,220 1,503,600
2023-03-31 $25,600,825 369,367
2023-03-31 $119,934,024 1,730,400
2023-03-31 $192,834,282 2,782,200
2022-12-31 $221,573,766 3,079,552
2022-12-31 $219,742,495 3,054,100
2022-12-31 $256,595,285 3,566,300
2022-09-30 $213,717,867 3,006,300
2022-09-30 $15,813,472 222,443
2022-09-30 $269,224,939 3,787,100
2022-06-30 $252,113,400 3,274,200
2022-06-30 $305,074,000 3,962,000
2022-06-30 $75,551,553 981,189
2022-03-31 $243,416,293 3,333,100
2022-03-31 $294,617,626 4,034,200

Report a Problem

Category
Description
Email (optional, for follow-up)